Vaccine to Target Guanylyl Cyclase C for Oncology is under clinical development by Liminatus Pharma and currently in Phase II for Gastric Cancer. According to GlobalData, Phase II drugs for Gastric Cancer have a 30% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Vaccine to Target Guanylyl Cyclase C for Oncology’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Vaccine to Target Guanylyl Cyclase C for Oncology overview
Ad5-hGCC-PADRE vaccine is under development for the treatment of metastatic cancers related to gastrointestinal adenocarcinomas (adenocarcinoma of the gastroesophageal junction), pancreatic ductal adenocarcinoma, colorectal adenocarcinoma, gastric adenocarcinoma and esophageal adenocarcinoma. The vaccine candidate is administered through intramuscular route. It is replication-deficient human type 5 recombinant adenovirus (Ad5) that is truncated with human guanylyl cyclase C (GCC) construct and having CD4 T helper cell epitope (PADRE). The vaccine candidate comprises of a protein fragment or a variant of protein (antigen) which induces specific immune responses.
Liminatus Pharma overview
Liminatus Pharma, a subsidiary of Feelux Co Ltd, focuses on the development and commercialization of chimeric antigen receptor T (CAR-T) cell therapies for cancer. It is investigating Ad5 F35-hGCC-Padre, a guanylyl cyclase C (GCC) cancer vaccine candidate that destroys the tumor cells without damaging the GCC and normal cells in the large intestine and prevents the recurrence and metastasis of cancers related to gastrointestinal adenocarcinomas. The company is also developing GCC targeted CAR-T therapeutics to treat colorectal, pancreatic, esophageal and gastric cancers. It incorporates its unique third-generation CAR-T technology to develop cell therapies. Liminatus is headquartered in La Palma, California, the US.
For a complete picture of Vaccine to Target Guanylyl Cyclase C for Oncology’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
